Amgen's 2008 earnings call highlighted stable financial performance with steady revenue and EPS growth, despite challenges in its anemia franchise. The company's focus on Denosumab's anticipated launch, its promising pipeline developments, and cost management strategies indicate positive momentum. However, uncertainties related to biosimilar competition in Europe and Aranesp's U.S. market pose risks. The overall tone was cautious but optimistic, suggesting measured confidence in achieving growth targets. Given these dynamics, the short-term impact on Amgenâ€™s stock is likely to be neutral to slightly positive.

[0]